Latest Manufacturing And Distribution News

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Pure One Corporation has made strides in zero-emission commercial vehicles with new battery-swap and electric models arriving in Australia, backed by a strengthened balance sheet from a $3.5 million tranche of Turquoise Group sale proceeds.

ClearVue Technologies bolstered its balance sheet with a A$6 million capital raise while landing high-profile projects including Canva’s Sydney HQ and its first European contract in Cyprus. The company also advanced international expansion and achieved key certifications confirming product durability and safety.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

Electro Optic Systems (ASX:EOS) posted a 284% surge in first-half 2026 revenue to $169 million, driven by robust defence contracts and regional tensions. Its order book hit a historic $846 million, prompting an upgrade to full-year guidance and signalling strong momentum in counter-drone and laser weapon systems.

Radiopharm Theranostics reported robust Phase 2b results for RAD101 in brain metastases imaging, hitting 93% concordance with MRI and setting the stage for a U.S. Phase 3 trial. Meanwhile, its Phase 1 trial of RAD204 showed durable partial responses and good tolerability in advanced solid tumors.

LTR Pharma has locked in a comprehensive commercial agreement with Strive Pharmacy, cementing its manufacturing and fulfilment infrastructure for the upcoming US launch of ROXUS®.

ClearVue Technologies has inked a manufacturing and distribution agreement with Aria Glass Industries, marking a major step into India’s booming construction sector backed by a US$240 million investment.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

MyEco Group has extended its partnership with Penrith City Council by winning a 3-to-5-year contract to supply compostable caddy liners for the council's FOGO program, aligning with NSW's mandated organics recycling rollout.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.